Health Economics›Mantle cell lymphoma›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Mantle cell lymphoma · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Rituximab Variant #05	—	R 391 307	56d	~65.3 mo	—	~36	~R 14 087 044 PFS proxy · indirect	—
Ibrutinib and Venetoclax Variant #01	—	R 250 300	28d	~31.3 mo	—	~35	~R 8 760 484 PFS proxy · indirect	1
Obinutuzumab monotherapy Variant #03	—	R 166 941	21d	—	—	—	—	—
Arsenic trioxide and Chlorambucil Variant #01	—	R 164 286	42d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	—	~8.5 mo	—	—	1
Bortezomib and Rituximab (VR) Variant #06	—	R 64 235	35d	~12.8 mo	—	~12	~R 770 814 PFS proxy · indirect	1
Temsirolimus and Rituximab Variant #01 Partial	—	R 58 980	28d	—	—	—	—	—
BDR Variant #02	—	R 32 826	84d	—	—	—	—	—
R-BL Variant #02	—	R 29 259	28d	—	—	—	—	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~7	~R 128 518 PFS proxy · indirect	15
BeRT Variant #01 Partial	—	R 17 215	28d	—	—	—	—	—
Bortezomib monotherapy Variant #14	—	R 8 539	35d	~30.3 mo	—	~27	~R 230 565 PFS proxy · indirect	5
PEP-C Variant #01 Partial	—	R 110	—	—	—	—	—	—
RT-PEPC N/A - protocol Partial	—	R 0	120d	—	—	—	—	—
Brexucabtagene autoleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Pirtobrutinib monotherapy Variant #01 Partial	—	—	28d	~14.0 mo	—	~16	—	1
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

17 of 17 regimens shown